{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T10:11:05Z","timestamp":1777111865461,"version":"3.51.4"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2015,5,22]],"date-time":"2015-05-22T00:00:00Z","timestamp":1432252800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1007\/s10620-015-3699-4","type":"journal-article","created":{"date-parts":[[2015,5,21]],"date-time":"2015-05-21T06:46:53Z","timestamp":1432190813000},"page":"2873-2880","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Clinical Presentation and Outcomes of Autoimmune Hepatitis in Inflammatory Bowel Disease"],"prefix":"10.1007","volume":"60","author":[{"given":"Ersilia M.","family":"DeFilippis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonal","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,5,22]]},"reference":[{"key":"3699_CR1","doi-asserted-by":"crossref","first-page":"7327","DOI":"10.3748\/wjg.v19.i42.7327","volume":"19","author":"M Rojas-Feria","year":"2013","unstructured":"Rojas-Feria M, Castro M, Su\u00e1rez E, Ampuero J, Romero-G\u00f3mez M. Hepatobiliary manifestations in inflammatory bowel disease: the gut, the drugs and the liver. World J Gastroenterol. 2013;19:7327\u20137340.","journal-title":"World J Gastroenterol"},{"key":"3699_CR2","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1002\/ibd.21219","volume":"16","author":"U Navaneethan","year":"2010","unstructured":"Navaneethan U, Shen B. Hepatopancreatobiliary manifestations and complications associated with inflammatory bowel disease. Inflamm Bowel Dis. 2010;16:1598\u20131619.","journal-title":"Inflamm Bowel Dis"},{"key":"3699_CR3","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3748\/wjg.14.331","volume":"14","author":"R Saich","year":"2008","unstructured":"Saich R, Chapman R. Primary sclerosing cholangitis, autoimmune hepatitis and overlap syndromes in inflammatory bowel disease. World J Gastroenterol. 2008;14:331\u2013337.","journal-title":"World J Gastroenterol"},{"key":"3699_CR4","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/0168-8278(92)90178-R","volume":"14","author":"R Perdigoto","year":"1992","unstructured":"Perdigoto R, Carpenter HA, Czaja AJ. Frequency and significance of chronic ulcerative colitis in severe corticosteroid-treated autoimmune hepatitis. J Hepatol. 1992;14:325\u2013331.","journal-title":"J Hepatol"},{"key":"3699_CR5","doi-asserted-by":"crossref","first-page":"S149","DOI":"10.14309\/00000434-201410002-00504","volume":"109","author":"J Bailey","year":"2014","unstructured":"Bailey J, Sreepati G, Love J, et al. Autoimmune hepatitis with inflammatory bowel disease is distinct and may be more refractory to traditional treatment. Am J Gastroenterol. 2014;109:S149.","journal-title":"Am J Gastroenterol"},{"key":"3699_CR6","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.clinre.2011.10.007","volume":"36","author":"PJ Trivedi","year":"2012","unstructured":"Trivedi PJ, Chapman RW. PSC, AIH and overlap syndrome in inflammatory bowel disease. Clin Res Hepatol Gastroenterol. 2012;36:420\u2013436.","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"3699_CR7","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1586\/egh.09.53","volume":"3","author":"C Knight","year":"2009","unstructured":"Knight C, Murray KF. Hepatobiliary associations with inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2009;3:681\u2013691.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"3699_CR8","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.autrev.2013.11.009","volume":"13","author":"R Liberal","year":"2014","unstructured":"Liberal R, Grant CR, Longhi MS, Mieli-Vergani G, Vergani D. Diagnostic criteria of autoimmune hepatitis. Autoimmun Rev. 2014;13:435\u2013440.","journal-title":"Autoimmun Rev"},{"key":"3699_CR9","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/hep.22322","volume":"48","author":"EM Hennes","year":"2008","unstructured":"Hennes EM, Zeniya M, Czaja AJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008;48:169\u2013176.","journal-title":"Hepatology"},{"key":"3699_CR10","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1002\/ibd.22864","volume":"18","author":"F Ordonez","year":"2012","unstructured":"Ordonez F, Lacaille F, Canioni D, et al. Pediatric ulcerative colitis associated with autoimmune diseases: a distinct form of inflammatory bowel disease? Inflamm Bowel Dis. 2012;18:1809\u20131817.","journal-title":"Inflamm Bowel Dis"},{"key":"3699_CR11","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.26494","volume":"59","author":"B Chassaing","year":"2014","unstructured":"Chassaing B, Etienne-Mesmin L, Gewirtz AT. Microbiota-liver axis in hepatic disease. Hepatology. 2014;59:328\u2013339.","journal-title":"Hepatology"},{"key":"3699_CR12","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.cbi.2012.12.004","volume":"201","author":"PP Trivedi","year":"2013","unstructured":"Trivedi PP, Jena GB. Ulcerative colitis-induced hepatic damage in mice: studies on inflammation, fibrosis, oxidative DNA damage and GST-P expression. Chem Biol Interact. 2013;201:19\u201330.","journal-title":"Chem Biol Interact"},{"key":"3699_CR13","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/labinvest.2014.93","volume":"94","author":"S Celaj","year":"2014","unstructured":"Celaj S, Gleeson MW, Deng J, et al. The microbiota regulates susceptibility to Fas-mediated acute hepatic injury. Lab Invest. 2014;94:938\u2013949.","journal-title":"Lab Invest"},{"key":"3699_CR14","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1155\/2013\/198070","volume":"27","author":"AJ Czaja","year":"2013","unstructured":"Czaja AJ. Diagnosis and management of the overlap syndromes of autoimmune hepatitis. Can J Gastroenterol. 2013;27:417\u2013423.","journal-title":"Can J Gastroenterol"},{"key":"3699_CR15","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jhep.2010.09.002","volume":"54","author":"KM Boberg","year":"2011","unstructured":"Boberg KM, Chapman RW, Hirschfield GM, et al. Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. J Hepatol. 2011;54:374\u2013385.","journal-title":"J Hepatol"},{"key":"3699_CR16","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3109\/15513815.2014.898721","volume":"33","author":"CP Rojas","year":"2014","unstructured":"Rojas CP, Bodicharla R, Campuzano-Zuluaga G, Hernandez L, Rodriguez MM. Autoimmune hepatitis and primary sclerosing cholangitis in children and adolescents. Fetal Pediatr Pathol. 2014;33:202\u2013209.","journal-title":"Fetal Pediatr Pathol"},{"key":"3699_CR17","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1002\/hep.26454","volume":"58","author":"M Deneau","year":"2013","unstructured":"Deneau M, Jensen MK, Holmen J, Williams MS, Book LS, Guthery SL. Primary sclerosing cholangitis, autoimmune hepatitis, and overlap in Utah children: epidemiology and natural history. Hepatology. 2013;58:1392\u20131400.","journal-title":"Hepatology"},{"key":"3699_CR18","first-page":"326","volume":"58","author":"AJ Czaja","year":"2013","unstructured":"Czaja AJ. The overlap syndromes of autoimmune hepatitis. Dig Dis Sci. 2013;58:326\u2013343.","journal-title":"Dig Dis Sci"},{"key":"3699_CR19","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1159\/000273735","volume":"82","author":"TA Malik","year":"2010","unstructured":"Malik TA, Gutierrez AM, McGuire B, Zarzour JG, Mukhtar F, Bloomer J. Autoimmune hepatitis-primary sclerosing cholangitis overlap syndrome complicated by Crohn\u2019s disease. Digestion. 2010;82:24\u201326.","journal-title":"Digestion"},{"key":"3699_CR20","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1007\/s10620-012-2378-y","volume":"58","author":"M Durazzo","year":"2013","unstructured":"Durazzo M, Premoli A, Paschetta E, Belci P, Spandre M, Bo S. Overlap syndromes of autoimmune hepatitis: an open question. Dig Dis Sci. 2013;58:344\u2013348.","journal-title":"Dig Dis Sci"},{"key":"3699_CR21","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1111\/j.1572-0241.2005.41841.x","volume":"100","author":"A Floreani","year":"2005","unstructured":"Floreani A, Rizzotto ER, Ferrara F, et al. Clinical course and outcome of autoimmune hepatitis\/primary sclerosing cholangitis overlap syndrome. Am J Gastroenterol. 2005;100:1516\u20131522.","journal-title":"Am J Gastroenterol"},{"key":"3699_CR22","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1007\/BF01296509","volume":"37","author":"M Rabinovitz","year":"1992","unstructured":"Rabinovitz M, Demetris AJ, Bou-Abboud CF, Van Thiel DH. Simultaneous occurrence of primary sclerosing cholangitis and autoimmune chronic active hepatitis in a patient with ulcerative colitis. Dig Dis Sci. 1992;37:1606\u20131611.","journal-title":"Dig Dis Sci"},{"key":"3699_CR23","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1055\/s-2007-1007301","volume":"14","author":"SP Lawrence","year":"1994","unstructured":"Lawrence SP, Sherman KE, Lawson JM, Goodman ZD. A 39\u00a0year old man with chronic hepatitis. Semin Liver Dis. 1994;14:97\u2013105.","journal-title":"Semin Liver Dis"},{"key":"3699_CR24","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1002\/hep.1840220537","volume":"22","author":"D Wurbs","year":"1995","unstructured":"Wurbs D, Klein R, Terracciano LM, Berg PA, Bianchi L. A 28-year-old woman with a combined hepatitic\/cholestatic syndrome. Hepatology. 1995;22:1598\u20131605.","journal-title":"Hepatology"},{"key":"3699_CR25","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1002\/hep.510230612","volume":"23","author":"KM Boberg","year":"1996","unstructured":"Boberg KM, Fausa O, Haaland T, et al. Features of autoimmune hepatitis in primary sclerosing cholangitis: an evaluation of 114 primary sclerosing cholangitis patients according to a scoring system for the diagnosis of autoimmune hepatitis. Hepatology. 1996;23:1369\u20131376.","journal-title":"Hepatology"},{"key":"3699_CR26","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1600-0676.1996.tb00743.x","volume":"16","author":"U Protzer","year":"1996","unstructured":"Protzer U, Dienes HP, Bianchi L, et al. Post-infantile giant cell hepatitis in patients with primary sclerosing cholangitis and autoimmune hepatitis. Liver. 1996;16:274\u2013282.","journal-title":"Liver"},{"key":"3699_CR27","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1023\/A:1018845829198","volume":"42","author":"VA Luketic","year":"1997","unstructured":"Luketic VA, Gomez DA, Sanyal AJ, Shiffman ML. An atypical presentation for primary sclerosing cholangitis. Dig Dis Sci. 1997;42:2009\u20132016.","journal-title":"Dig Dis Sci"},{"key":"3699_CR28","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/j.1572-0241.1998.224_a.x","volume":"93","author":"AN McNair","year":"1998","unstructured":"McNair AN, Moloney M, Portmann BC, Williams R, McFarlane IG. Autoimmune hepatitis overlapping with primary sclerosing cholangitis in five cases. Am J Gastroenterol. 1998;93:777\u2013784.","journal-title":"Am J Gastroenterol"},{"key":"3699_CR29","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1002\/hep.1840360615","volume":"36","author":"AA Abdo","year":"2002","unstructured":"Abdo AA, Bain VG, Kichian K, Lee SS. Evolution of autoimmune hepatitis to primary sclerosing cholangitis: a sequential syndrome. Hepatology. 2002;36:1393\u20131399.","journal-title":"Hepatology"},{"key":"3699_CR30","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1034\/j.1600-0641.2000.033004543.x","volume":"33","author":"HR Buuren Van","year":"2000","unstructured":"Van Buuren HR, van Hoogstraten HJE, Terkivatan T, Schalm SW, Vleggaar FP. High prevalence of autoimmune hepatitis among patients with primary sclerosing cholangitis. J Hepatol.. 2000;33:543\u2013548.","journal-title":"J Hepatol."},{"key":"3699_CR31","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/00042737-200102000-00020","volume":"13","author":"GS Hatzis","year":"2001","unstructured":"Hatzis GS, Vassiliou VA, Delladetsima JK. Overlap syndrome of primary sclerosing cholangitis and autoimmune hepatitis. Eur J Gastroenterol Hepatol. 2001;13:203\u2013206.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"3699_CR32","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/hep.510280210","volume":"28","author":"AJ Czaja","year":"1998","unstructured":"Czaja AJ. Frequency and nature of the variant syndromes of autoimmune liver disease. Hepatology. 1998;28:360\u2013365.","journal-title":"Hepatology"},{"key":"3699_CR33","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/liv.12028","volume":"33","author":"C Rupp","year":"2013","unstructured":"Rupp C, Mummelthei A, Sauer P, et al. Non-IBD immunological diseases are a risk factor for reduced survival in PSC. Liver Int. 2013;33:86\u201393.","journal-title":"Liver Int"},{"key":"3699_CR34","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/MCG.0b013e318157c614","volume":"43","author":"S L\u00fcth","year":"2009","unstructured":"L\u00fcth S, Kanzler S, Frenzel C, et al. Characteristics and long-term prognosis of the autoimmune hepatitis\/primary sclerosing cholangitis overlap syndrome. J Clin Gastroenterol. 2009;43:75\u201380.","journal-title":"J Clin Gastroenterol"},{"key":"3699_CR35","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/ajd.12054","volume":"55","author":"LJ Dang","year":"2014","unstructured":"Dang LJ, Lubel JS, Gunatheesan S, Hosking P, Su J. Drug-induced lupus and autoimmune hepatitis secondary to infliximab for psoriasis. Australas J Dermatol. 2014;55:75\u201379.","journal-title":"Australas J Dermatol"},{"key":"3699_CR36","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1007\/s10620-014-3323-z","volume":"59","author":"B Yilmaz","year":"2014","unstructured":"Yilmaz B, Roach EC, Koklu S. Infliximab leading to autoimmune hepatitis: an increasingly recognized side effect. Dig Dis Sci. 2014;59:2602\u20132603.","journal-title":"Dig Dis Sci"},{"key":"3699_CR37","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.crohns.2010.12.007","volume":"5","author":"A Doyle","year":"2011","unstructured":"Doyle A, Forbes G, Kontorinis N. Autoimmune hepatitis during infliximab therapy for Crohn\u2019s disease: a case report. J Crohns Colitis. 2011;5:253\u2013255.","journal-title":"J Crohns Colitis"},{"key":"3699_CR38","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1007\/s10620-011-1748-1","volume":"56","author":"DA Goldfeld","year":"2011","unstructured":"Goldfeld DA, Verna EC, Lefkowitch J, Swaminath A. Infliximab-induced autoimmune hepatitis with successful switch to adalimumab in a patient with Crohn\u2019s disease: the index case. Dig Dis Sci. 2011;56:3386\u20133388.","journal-title":"Dig Dis Sci"},{"key":"3699_CR39","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2165\/11586210-000000000-00000","volume":"24","author":"M Cravo","year":"2010","unstructured":"Cravo M, Silva R, Serrano M. Autoimmune hepatitis induced by infliximab in a patient with Crohn\u2019s disease with no relapse after switching to adalimumab. BioDrugs Clin Immunother Biopharm Gene Therapy. 2010;24:25\u201327.","journal-title":"BioDrugs Clin Immunother Biopharm Gene Therapy"},{"key":"3699_CR40","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.crohns.2012.01.017","volume":"6","author":"C Casteren-Messidoro Van","year":"2012","unstructured":"Van Casteren-Messidoro C, Prins G, van Tilburg A, Zelinkova Z, Schouten J, de Man R. Autoimmune hepatitis following treatment with infliximab for inflammatory bowel disease. J Crohns Colitis. 2012;6:630\u2013631.","journal-title":"J Crohns Colitis"},{"key":"3699_CR41","doi-asserted-by":"crossref","first-page":"E149","DOI":"10.1002\/ibd.21880","volume":"17","author":"K Subramaniam","year":"2011","unstructured":"Subramaniam K, Chitturi S, Brown M, Pavli P. Infliximab-induced autoimmune hepatitis in Crohn\u2019s disease treated with budesonide and mycophenolate. Inflamm Bowel Dis. 2011;17:E149\u2013E150.","journal-title":"Inflamm Bowel Dis"},{"key":"3699_CR42","doi-asserted-by":"crossref","first-page":"524","DOI":"10.5694\/j.1326-5377.2007.tb01396.x","volume":"187","author":"G Ozorio","year":"2007","unstructured":"Ozorio G, McGarity B, Bak H, Jordan AS, Lau H, Marshall C. Autoimmune hepatitis following infliximab therapy for ankylosing spondylitis. Med J Aust. 2007;187:524\u2013526.","journal-title":"Med J Aust"},{"key":"3699_CR43","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/ibd.20293","volume":"14","author":"M Marques","year":"2008","unstructured":"Marques M, Magro F, Cardoso H, et al. Infliximab-induced lupus-like syndrome associated with autoimmune hepatitis. Inflamm Bowel Dis. 2008;14:723\u2013725.","journal-title":"Inflamm Bowel Dis"},{"key":"3699_CR44","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1136\/ard.2004.032821","volume":"64","author":"V Germano","year":"2005","unstructured":"Germano V, Picchianti Diamanti A, Baccano G, et al. Autoimmune hepatitis associated with infliximab in a patient with psoriatic arthritis. Ann Rheum Dis. 2005;64:1519\u20131520.","journal-title":"Ann Rheum Dis"},{"key":"3699_CR45","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/j.1365-2230.2008.03088.x","volume":"34","author":"DA Fairhurst","year":"2009","unstructured":"Fairhurst DA, Sheehan-Dare R. Autoimmune hepatitis associated with infliximab in a patient with palmoplantar pustular psoriasis. Clin Exp Dermatol. 2009;34:421\u2013422.","journal-title":"Clin Exp Dermatol"},{"key":"3699_CR46","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/BOR.0b013e32835b1366","volume":"25","author":"R Perez-Alvarez","year":"2013","unstructured":"Perez-Alvarez R, P\u00e9rez-de-Lis M, Ramos-Casals M. BIOGEAS study group: biologics-induced autoimmune diseases. Curr Opin Rheumatol. 2013;25:56\u201364.","journal-title":"Curr Opin Rheumatol"},{"key":"3699_CR47","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.autrev.2012.03.010","volume":"12","author":"C Efe","year":"2013","unstructured":"Efe C. Drug induced autoimmune hepatitis and TNF-\u03b1 blocking agents: is there a real relationship? Autoimmun Rev. 2013;12:337\u2013339.","journal-title":"Autoimmun Rev"},{"key":"3699_CR48","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s10067-008-0885-1","volume":"27","author":"K Harada","year":"2008","unstructured":"Harada K, Akai Y, Koyama S, Ikenaka Y, Saito Y. A case of autoimmune hepatitis exacerbated by the administration of etanercept in the patient with rheumatoid arthritis. Clin Rheumatol. 2008;27:1063\u20131066.","journal-title":"Clin Rheumatol"},{"key":"3699_CR49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/956463","volume":"2014","author":"R Parekh","year":"2014","unstructured":"Parekh R, Kaur N. Liver injury secondary to anti-TNF-alpha therapy in inflammatory bowel disease: a case series and review of the literature. Case Rep Gastrointest Med. 2014;2014:1\u20135.","journal-title":"Case Rep Gastrointest Med"},{"key":"3699_CR50","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1097\/MCG.0b013e3181a745e7","volume":"44","author":"T Adar","year":"2010","unstructured":"Adar T, Mizrahi M, Pappo O, Scheiman-Elazary A, Shibolet O. Adalimumab-induced autoimmune hepatitis. J Clin Gastroenterol. 2010;44:e20\u2013e22.","journal-title":"J Clin Gastroenterol"},{"key":"3699_CR51","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1136\/ard.2004.024182","volume":"64","author":"C Eriksson","year":"2005","unstructured":"Eriksson C, Engstrand S, Sundqvist K-G, Rantap\u00e4\u00e4-Dahlqvist S. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha. Ann Rheum Dis. 2005;64:403\u2013407.","journal-title":"Ann Rheum Dis"},{"key":"3699_CR52","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1007\/s10067-005-0169-y","volume":"26","author":"GJ Tobon","year":"2007","unstructured":"Tobon GJ, Ca\u00f1as C, Jaller J-J, Restrepo J-C, Anaya J-M. Serious liver disease induced by infliximab. Clin Rheumatol. 2007;26:578\u2013581.","journal-title":"Clin Rheumatol"},{"key":"3699_CR53","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1034\/j.1600-0528.2002.017411.x","volume":"174","author":"AM Diehl","year":"2000","unstructured":"Diehl AM. Cytokine regulation of liver injury and repair. Immunol Rev. 2000;174:160\u2013171.","journal-title":"Immunol Rev"},{"key":"3699_CR54","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.jhep.2013.05.046","volume":"59","author":"J Rajanayagam","year":"2013","unstructured":"Rajanayagam J, Lewindon PJ. Infliximab as rescue therapy in paediatric autoimmune hepatitis. J Hepatol. 2013;59:908\u2013909.","journal-title":"J Hepatol"},{"key":"3699_CR55","doi-asserted-by":"crossref","unstructured":"Vallejo Senra N, Fern\u00e1ndez Castroagud\u00edn J, Molina P\u00e9rez E, Dom\u00ednguez-Mu\u00f1oz JE. Onset of severe acute autoimmune hepatitis refractory to conventional treatment, rescued with infliximab. Gastroenterol Hepatol. 2014. doi: 10.1016\/j.gastrohep.2014.02.012 .","DOI":"10.1016\/j.gastrohep.2014.02.012"},{"key":"3699_CR56","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jhep.2012.11.010","volume":"58","author":"C Weiler-Normann","year":"2013","unstructured":"Weiler-Normann C, Schramm C, Quaas A, et al. Infliximab as a rescue treatment in difficult-to-treat autoimmune hepatitis. J Hepatol. 2013;58:529\u2013534.","journal-title":"J Hepatol"},{"key":"3699_CR57","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.autrev.2003.09.003","volume":"3","author":"I Diamantis","year":"2004","unstructured":"Diamantis I, Boumpas DT. Autoimmune hepatitis: evolving concepts. Autoimmun Rev. 2004;3:207\u2013214.","journal-title":"Autoimmun Rev"},{"key":"3699_CR58","doi-asserted-by":"crossref","first-page":"33","DOI":"10.5582\/irdr.2014.01034","volume":"4","author":"T Tanaka","year":"2015","unstructured":"Tanaka T, Sugawara Y, Kokudo N. Liver transplantation and autoimmune hepatitis. Intractable Rare Dis Res. 2015;4:33\u201338.","journal-title":"Intractable Rare Dis Res"},{"key":"3699_CR59","unstructured":"Seaberg EC, Belle SH, Beringer KC, Schivins JL, Detre KM. Liver transplantation in the United States from 1987\u20131998: updated results from the Pitt-UNOS Liver Transplant Registry. Clin Transpl. 1998;17\u201337."},{"key":"3699_CR60","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1053\/jlts.2002.32981","volume":"8","author":"EP Molmenti","year":"2002","unstructured":"Molmenti EP, Netto GJ, Murray NG, et al. Incidence and recurrence of autoimmune\/alloimmune hepatitis in liver transplant recipients. Liver Transplant. 2002;8:519\u2013526.","journal-title":"Liver Transplant"},{"key":"3699_CR61","doi-asserted-by":"crossref","first-page":"S462","DOI":"10.1111\/j.1872-034X.2007.00287.x","volume":"37","author":"AW Lohse","year":"2007","unstructured":"Lohse AW, Weiler-Norman C, Burdelski M. De novo autoimmune hepatitis after liver transplantation. Hepatol Res. 2007;37:S462.","journal-title":"Hepatol Res"},{"key":"3699_CR62","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1097\/00007890-199812270-00013","volume":"66","author":"E Prados","year":"1998","unstructured":"Prados E, Cuervas-Mons V, de la Mata M, et al. Outcome of autoimmune hepatitis after liver transplantation. Transplantation. 1998;66:1645\u20131650.","journal-title":"Transplantation"},{"key":"3699_CR63","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/00007890-199907270-00016","volume":"68","author":"P Milkiewicz","year":"1999","unstructured":"Milkiewicz P, Hubscher SG, Skiba G, Hathaway M, Elias E. Recurrence of autoimmune hepatitis after liver transplantation. Transplantation. 1999;68:253\u2013256.","journal-title":"Transplantation"},{"key":"3699_CR64","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1399-0012.2010.01221.x","volume":"25","author":"I Aguilera","year":"2011","unstructured":"Aguilera I, Sousa JM, Praena JM, G\u00f3mez-Bravo MA, N\u00fa\u00f1ez-Roldan A. Choice of calcineurin inhibitor may influence the development of de novo immune hepatitis associated with anti-GSTT1 antibodies after liver transplantation. Clin Transplant. 2011;25:207\u2013212.","journal-title":"Clin Transplant"},{"key":"3699_CR65","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1111\/j.1600-6143.2006.01717.x","volume":"7","author":"RS Venick","year":"2007","unstructured":"Venick RS, McDiarmid SV, Farmer DG, et al. Rejection and steroid dependence: unique risk factors in the development of pediatric posttransplant de novo autoimmune hepatitis. Am J Transplant. 2007;7:955\u2013963.","journal-title":"Am J Transplant"},{"key":"3699_CR66","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1053\/jhep.2002.31167","volume":"35","author":"M Salcedo","year":"2002","unstructured":"Salcedo M, Vaquero J, Ba\u00f1ares R, et al. Response to steroids in de novo autoimmune hepatitis after liver transplantation. Hepatology. 2002;35:349\u2013356.","journal-title":"Hepatology"},{"key":"3699_CR67","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S0140-6736(97)06478-7","volume":"351","author":"N Kerkar","year":"1998","unstructured":"Kerkar N, Hadzi\u0107 N, Davies ET, et al. De-novo autoimmune hepatitis after liver transplantation. Lancet. 1998;351:409\u2013413.","journal-title":"Lancet"},{"key":"3699_CR68","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1002\/lt.21525","volume":"14","author":"J Campsen","year":"2008","unstructured":"Campsen J, Zimmerman MA, Trotter JF, et al. Liver transplantation for autoimmune hepatitis and the success of aggressive corticosteroid withdrawal. Liver Transplant. 2008;14:1281\u20131286.","journal-title":"Liver Transplant"},{"key":"3699_CR69","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1365-2036.2012.05141.x","volume":"36","author":"A Sandhu","year":"2012","unstructured":"Sandhu A, Alameel T, Dale CH, Levstik M, Chande N. The safety and efficacy of antitumour necrosis factor-alpha therapy for inflammatory bowel disease in patients post liver transplantation: a case series. Aliment Pharmacol Ther. 2012;36:159\u2013165.","journal-title":"Aliment Pharmacol Ther"},{"key":"3699_CR70","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1111\/j.1600-6143.2006.01333.x","volume":"6","author":"RC Verdonk","year":"2006","unstructured":"Verdonk RC, Dijkstra G, Haagsma EB, et al. Inflammatory bowel disease after liver transplantation: risk factors for recurrence and de novo disease. Am J Transplant. 2006;6:1422\u20131429.","journal-title":"Am J Transplant"},{"key":"3699_CR71","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1136\/gut.43.5.639","volume":"43","author":"GV Papatheodoridis","year":"1998","unstructured":"Papatheodoridis GV, Hamilton M, Mistry PK, Davidson B, Rolles K, Burroughs AK. Ulcerative colitis has an aggressive course after orthotopic liver transplantation for primary sclerosing cholangitis. Gut.. 1998;43:639\u2013644.","journal-title":"Gut."},{"key":"3699_CR72","first-page":"279","volume":"92","author":"TR Riley","year":"1997","unstructured":"Riley TR, Schoen RE, Lee RG, Rakela J. A case series of transplant recipients who despite immunosuppression developed inflammatory bowel disease. Am J Gastroenterol. 1997;92:279\u2013282.","journal-title":"Am J Gastroenterol"},{"key":"3699_CR73","doi-asserted-by":"crossref","unstructured":"McDonald JWD, Feagan BG, Jewell DP, Brynskov J, Stange EF, Macdonald JK. Cyclosporine for induction of remission in Crohn\u2019s disease. Cochrane Database Syst Rev. 2005. doi: 10.1002\/14651858.CD000297.pub2 .","DOI":"10.1002\/14651858.CD000297.pub2"},{"key":"3699_CR74","doi-asserted-by":"crossref","unstructured":"Shibolet O, Regushevskaya E, Brezis M, Soares-Weiser K. Cyclosporine A for induction of remission in severe ulcerative colitis. Cochrane Database Syst Rev. 2005. doi: 10.1002\/14651858.CD004277.pub2 .","DOI":"10.1002\/14651858.CD004277.pub2"},{"key":"3699_CR75","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/ibd.20263","volume":"14","author":"A Benson","year":"2008","unstructured":"Benson A, Barrett T, Sparberg M, Buchman AL. Efficacy and safety of tacrolimus in refractory ulcerative colitis and Crohn\u2019s disease: a single-center experience. Inflamm Bowel Dis. 2008;14:7\u201312.","journal-title":"Inflamm Bowel Dis"},{"key":"3699_CR76","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1046\/j.1365-2036.2000.00695.x","volume":"14","author":"K Fellermann","year":"2000","unstructured":"Fellermann K, Steffen M, Stein J, et al. Mycophenolate mofetil: lack of efficacy in chronic active inflammatory bowel disease. Aliment Pharmacol Ther. 2000;14:171\u2013176.","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-015-3699-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-015-3699-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-015-3699-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T12:06:40Z","timestamp":1599048400000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-015-3699-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,22]]},"references-count":76,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["3699"],"URL":"https:\/\/doi.org\/10.1007\/s10620-015-3699-4","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,22]]}}}